Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients

SpringerPlus

Table 6 Univariate analysis of the combination of EGFR mutational status, CEA and sEGFR for PFS and OS

			Progression-free survival		Overall survival		Univariate cox analysis
	Positive marker ^a	N	Me ^b (95% CI)	p ^c	Me ^b (95% CI)	p ^c	Progression			Death
	Positive marker ^a	N	Me ^b (95% CI)	p ^c	Me ^b (95% CI)	p ^c	HR	95% CI	p	HR	95% CI	p
sEGFR + Mutation Status	2	5	23.5(−)	0.018	9.9(0.0 – 23.0)	0.067	1.000			1.000
	1	14	7.0(4.9 – 9.0)		2.7(1.8 – 3.7)		2.497	0.782 – 7.979	0.123	4.050	0.904 – 18.148	0.068
	0	9	3.5(0.1 – 6.9)		2.7(1.4 – 4.1)		4.370	1.195 – 15.986	0.026	7.894	1.607 – 38.775	0.011
CEA + Mutation Status	2	4	6.2(0.0 – 13.3)	0.338	6.5(0.6 – 12.5)	0.045	1.000			1.000
	1	9	2.7(2.3 – 3.1)		10.2(2.8 – 17.6)		2.203	0.648 – 7.717	0.203	1.267	0.324 – 4.953	0.733
	0	7	3.5(2.6 – 4.3)		5.0(1.0 – 9.1)		2.508	0.660 – 9.526	0.177	4.393	1.000 – 19.297	0.050
CEA + sEGFR Patients with known mutation status	2	9	2.7(2.6 – 2.8)	0.689	10.5(9.6 – 11.4)	0.028	1.000			1.000
	1	8	3.1(0.03 – 6.2)		5.2(3.2 – 7.3)		1.422	0.486 – 4.158	0.520	2.568	0.833 – 7.920	0.101
	0	3	3.5(2.0 – 5.0)		4.2(3.0 – 5.4)		1.787	0.426 – 7.491	0.427	7.433	1.448 – 38.170	0.016
CEA + sEGFR all patients	2	14	3.2(0.0 – 7.2)	0.229	12.6(5.7 – 19.4)	0.003	1.000			1.000
	1	16	2.6(1.9 – 3.4)		5.2(2.4 – 8.0)		1.931	0.840 – 7.305	0.121	2.962	1.170 – 7.496	0.022
	0	4	2.5(1.4 – 3.7)		3.5(1.6 – 5.3)		2.192	0.658 – 7.305	0.201	8.359	2.111 – 33.095	0.002

Abbreviations: Me Median, HR Hazard Ratio, CI Confidence interval.
^a(2) both markers positive (above the cut-off point or mutated EGFR), (1) only one positive and (0) both negative (below the cut-off point or WT EGFR); ^bMonths; ^cp value calculated using the Log-Rank test.